Quizartinib

Drug Profile

Quizartinib

Alternative Names: AC-010220; AC-220; ASP-2689

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Ambit Biosciences Corporation
  • Developer Cancer Research UK; Cardiff University; Daiichi Sankyo Company; University of Texas M. D. Anderson Cancer Center
  • Class 3-ring heterocyclic compounds; Antineoplastics; Benzothiazoles; Imidazoles; Isoxazoles; Morpholines; Phenylurea compounds; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • Phase II/III Myelodysplastic syndromes
  • No development reported Acute lymphoblastic leukaemia; Solid tumours

Most Recent Events

  • 04 May 2017 The University of Hong Kong plans a phase II trial of quizartinib plus omacetaxine mepesuccinate for Acute myeloid leukaemia (Combination therapy; Second-line therapy or greater; Newly diagnosed) (NCT03135054)
  • 01 Apr 2017 Pharmacodynamics data from a preclinical trial in Acute myeloid leukaemia presented at the 108th annual meeting of the American Association for Cancer Research (AACR-2017)
  • 03 Dec 2016 Leukaemia and Lymphoma Research Institute and National Cancer Research Institute terminates the AML-LI-1 trial in Acute myeloid leukaemia (Combination therapy, First line therapy) in United Kingdom and Denmark
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top